Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (11)

Company Market Cap Price
ABT Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
$217.70B
$125.42
+0.01%
AMGN Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
$177.60B
$331.94
-2.42%
VTRS Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
$12.74B
$11.00
+2.23%
RDY Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
$11.84B
$14.19
+0.32%
AMRX Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
$3.83B
$12.18
+2.01%
OGN Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
$1.86B
$7.41
+3.71%
HROW Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
$1.69B
$45.90
-1.87%
AMPH Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
$1.24B
$26.77
-1.40%
KMDA Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
$406.96M
$7.04
-0.98%
RANI Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
$114.27M
$1.62
+3.18%
SCNX Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
$9.84M
$0.61
+0.64%

Loading company comparison...

Loading research report...

VTRS Viatris Inc.

Viatris Sells $815 Million Equity Stake in Biocon Biologics

Dec 06, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Reports Strong Interim Phase 4 Results for CREXONT in Parkinson’s Disease

Dec 05, 2025
AMGN Amgen Inc.

Accord Healthcare Launches Denosumab Biosimilars Osvyrti and Jubereq, Challenging Amgen’s Prolia and Xgeva

Dec 02, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Secures FDA Approval for Generic Albuterol Inhalation Aerosol

Dec 02, 2025
ABT Abbott Laboratories

Abbott Launches U.S. Correction for FreeStyle Libre 3 Sensors After Falsely Low Readings Detected

Nov 24, 2025
ABT Abbott Laboratories

Abbott Announces $21 B Acquisition of Exact Sciences, Strengthening Cancer Diagnostics Portfolio

Nov 20, 2025
HROW Harrow Health, Inc.

Harrow Health Completes Acquisition of Melt Pharmaceuticals, Expanding into Procedural Sedation

Nov 18, 2025
OGN Organon & Co.

Organon & Co. Secures First U.S. Approval for Pertuzumab Biosimilar POHERDY

Nov 17, 2025
AMRX Amneal Pharmaceuticals, Inc.

Amneal Receives FDA Approval for First‑to‑Market Generic Iohexol Injection, Expanding Contrast‑Agent Portfolio

Nov 14, 2025
KMDA Kamada Ltd.

Kamada Ltd. Reports Q3 2025 Earnings: Revenue Beats Estimates, Adjusted EBITDA Surges 34% YoY

Nov 10, 2025
AMGN Amgen Inc.

Amgen’s VESALIUS‑CV Trial Confirms Repatha’s Primary‑Prevention Benefit, Boosting Market Outlook

Nov 08, 2025
OGN Organon & Co.

Organon Sells JADA® System to Laborie for Up to $465 Million, Aiming to Reduce Debt

Nov 07, 2025

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks